Developmental Research Program

项目摘要/总结 (DRP) 乳腺癌经常具有特定模式的同源重组 (HR) DNA 修复缺陷 (HRD) 和/或遗传不稳定性的特定模式，即染色体不稳定性 (CIN) 和 APOBEC 诱变。 这些改变存在于相当大比例的乳腺癌中，并且在转移性乳腺癌中丰富。 疾病。可靠地识别这些患者并确定这些患者的最佳治疗方法的生物标志物 迫切需要。发展研究计划（DRP）将在促进转化方面发挥重要作用 专注于乳腺癌的研究工作，特别是针对 DNA 修复特定模式的研究 缺陷和/或遗传不稳定性及其分子基础。我们将使用 DRP 资金并辅以强大的 承诺机构资金支持新的和已建立的研究人员的创新项目，这些项目是 对于这一大类乳腺癌的诊断和治疗新想法的产生至关重要。我们的 目标是建立为重要新方向快速提供资金的机制，以加速实现 我们 SPORE 的转化研究目标。我们确定了一个可靠的、有前途的发展组合 研究项目，一旦该计划建立，这些项目将竞争支持。我们将要求飞行员 来自大型 MSKCC 内的临床和基础研究人员的具有转化潜力的项目提案 社区，包括洛克菲勒大学、纽约长老会医院和威尔康奈尔医学院 康奈尔大学的。经过严格的同行评审后，我们将选择最有前途的新项目进行支持 由领导委员会、内部顾问委员会和患者权益倡导者组成。外界的意见 将根据需要征求评审员的意见。试点项目将资助一年，但研究人员可以申请 明年将通过同样的竞争过程提供额外资金。每年的咨询和领导 委员会成员将开会审查每个研究项目、核心、职业提升项目和 发展试点项目。委员会成员将被要求评估是否有任何发展项目 已取得足够的进展并显示出足够的转化潜力，从而使完整的 SPORE 之一黯然失色 研究项目。然后，委员会成员将投票决定是否应该进行任何开发项目 推进至完整项目状态。如果是这样，预算将适当调整并报请批准。 NCI 的 TRP。

Project Abstract/ Summary (DRP) Breast cancers frequently harbor specific patterns of homologous recombination (HR) DNA repair defects (HRD) and/or specific patterns of genetic instability, namely chromosomal instability (CIN) and APOBEC mutagenesis. These alterations are present in a substantial proportion of breast cancers and they are enriched in metastatic disease. Biomarkers to identify these patients reliably and to define the optimal treatments for these patients are sorely needed. The Developmental Research Program (DRP) will play an important role in fostering translational research endeavors focusing on breast cancer, in particular research addressing specific patterns of DNA repair defects and/or genetic instability and their molecular basis. We will use DRP funding supplemented by a strong commitment of institutional funds to support innovative projects by new and established investigators, which are critical to the generation of new ideas in the diagnosis and treatment of this large subset of breast cancers. Our goal is to establish mechanisms for rapid funding of important new directions to accelerate progress towards the translational research goals of our SPORE. We identified a credible portfolio of promising developmental research projects, which will be competing for support once the program is established. We will request pilot project proposals with translational potential from clinical and basic investigators within the larger MSKCC community, including Rockefeller University, New York-Presbyterian Hospital and Weill Cornell Medical College of Cornell University. We will then select the most promising new projects for support after rigorous peer review by the Leadership Committee, the Internal Advisory Board and the Patient Advocates. The opinion of external reviewers will be solicited as needed. Pilot projects will be funded for 1 year, but investigators may apply for additional funding through this same competitive process the next year. Every year the Advisory and Leadership Committee members will meet to review each research project, core, career enhancement project and developmental pilot project. Committee members will be asked to assess whether any developmental project has progressed sufficiently and shown enough translational potential, so as to eclipse one of the full SPORE Research Projects. The committee members will then vote and decide whether any developmental project should be advanced to full project status. If so, the budgets will be appropriately adjusted and sent for approval with the TRP of the NCI.